Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKFree Report) in a report issued on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ EVOK opened at $0.58 on Friday. The company’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.62. Evoke Pharma has a 12 month low of $0.40 and a 12 month high of $1.77. The company has a market capitalization of $4.95 million, a P/E ratio of -0.31 and a beta of 0.38.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last released its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The business had revenue of $1.74 million during the quarter.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Featured Articles

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.